Lupus Nephritis – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Lupus Nephritis – Drugs In Development, 2023’, provides an overview of the Lupus Nephritis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Lupus Nephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lupus Nephritis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Lupus Nephritis
- The report reviews pipeline therapeutics for Lupus Nephritis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Lupus Nephritis therapeutics and enlists all their major and minor projects
- The report assesses Lupus Nephritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Lupus Nephritis
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Lupus Nephritis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lupus Nephritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
149 Bio LLCAbbVie Inc
Alexion Pharmaceuticals Inc
Alphamab Oncology
Alpine Immune Sciences Inc
Amgen Inc
Annexon Inc
Apellis Pharmaceuticals Inc
Aria Pharmaceuticals Inc
Asahi Kasei Pharma Corp
AstraZeneca Plc
Astria Therapeutics Inc
BeiGene Ltd
Beijing Mabworks Biotech Co Ltd
Bellvitge Biomedical Research Institute
BioAegis Therapeutics Inc
Biocon Ltd
Bristol-Myers Squibb Co
Cabaletta Bio Inc
Capricor Therapeutics Inc
Cellenkos Inc
Chinook Therapeutics Inc
Chugai Pharmaceutical Co Ltd
Corestemchemon Inc
Createrna Science and Technology Co Ltd
Eledon Pharmaceuticals Inc
Equillium Inc
Everest Medicines Ltd
F. Hoffmann-La Roche Ltd
Genrix (Shanghai) Biopharmaceutical Co Ltd
Horizon Therapeutics Plc
ImmPACT Bio USA Inc
ImmuneID Inc
Inflection Biosciences Ltd
Innovent Biologics Inc
Jiangsu Hengrui Medicine Co Ltd
JiangSu Qyuns Therapeutics Co Ltd
Jiangsu Ruiyuan Biotechnology Co Ltd
Johnson & Johnson
Juventas Cell Therapy Ltd
Kezar Life Sciences Inc
Kyverna Therapeutics Inc
Lepton Pharmaceuticals Ltd
MorphoSys AG
Mysthera Therapeutics AG
Neutrolis Inc
Nkarta Inc
Novartis AG
NovelMed Therapeutics Inc
Omeros Corp
Orbsen Therapeutics Ltd
Pfizer Inc
Ra Pharmaceuticals Inc
RemeGen Co Ltd
Resolve Therapeutics LLC
Sana Biotechnology Inc
SciRhom GmbH
Serenity Bioworks Inc
Slate Bio Inc
Transcenta Holding Ltd
UCB SA
University of Southern California
Zai Lab Ltd